LURIE CANCER CENTER ONCOSET SYMPOSIUM The Era of Transformative Molecular Oncology Robert H. Lurie Comprehensive Cancer Center of Northwestern University Chairs: Leonidas Platanias, MD, PhD Massimo Cristofanilli, MD Date: March 19, 2021 VIRTUAL EVENT - 9:00 A.M. - 4:30 P.M. CENTRAL TIME | MATERIALS AVAILABLE THROUGH APRIL 2 Lurie Cancer Center OncoSET Symposium: The Era of Transformative Molecular Oncology OPENING REMARKS 9:00 a.m. Welcome Leonidas Platanias, MD, PhD and Massimo Cristofanilli, MD Lurie Cancer Center KEYNOTE ADDRESS 9:05 a.m. The Evolution of Molecular Oncology: Actionable, Druggable, Undruggable? David Hong, MD The University of Texas MD Anderson Cancer Center SESSION 1: Molecularly Targeted Therapies and Immune Therapy Selection Co-Chairs: Amir Behdad, MD and Young Chae, MD, MPH, MBA, Lurie Cancer Center 9:45 a.m. The Central Role of Tumor and Germline DNA Alterations in Cancer Treatment Pamela Munster, MD UCSF Helen Diller Family Comprehensive Cancer Center 10:15 a.m. The Implementation of Precision Medicine in an Academic Center: It Takes a Village Milan Radovich, PhD Indiana University Simon Cancer Center 10:50 a.m. Panel Discussion 11:10 a.m. Break & Exhibits SESSION 2: Evolving Role of Liquid Biopsy: Detection, Monitoring and Early Detection Co-Chairs: Massimo Cristofanilli, MD and Dai Horiuchi, PhD, Lurie Cancer Center 11:40 p.m. Liquid Biopsy in Cancer Diagnostics: Fulfilling the Dream of Earlier Detection? Nickolas Papadopoulos, PhD Johns Hopkins Medicine 12:10 p.m. Precision Medicine Delivery in Metastatic Prostate Cancer: Foresight “2020” Manish Kohli, MD Huntsman Cancer Institute - University of Utah Health 12:50 p.m. Panel Discussion 1:10 p.m. Lunch & Exhibits March 19, 2021 | Virtual Event | Materials Available through April 2 SESSION 3: Drug Development Era of Precision Oncology: Predictive or Resistant Markers? Co-Chairs: Co-Chairs: Devalingam Mahalingam, MD and Jeffrey Sosman, MD, Lurie Cancer Center 2:10 p.m. Liquid Biopsies in Colorectal Cancer: A New Paradigm in Precision Medicine – Are We Ready? Aparna Parikh, MD Massachusetts General Hospital 2:45 p.m. Targeting B7 Family Immune Checkpoint as a New Potential Strategy for Breast Cancer Therapy Yong Wan, PhD Lurie Cancer Center 3:15 p.m. Development of Drugs that Effectively Target ESR1 Mutant Breast Cancers Geoffrey Greene, PhD The University of Chicago 3:50 p.m. Panel Discussion CONCLUSION 4:10 p.m. Closing Remarks Leonidas Platanias, MD, PhD and Massimo Cristofanilli, MD Lurie Cancer Center 4:30 p.m. Adjourn Helpful Information for Attendees Continuing Medical Education (CME) Credit: To claim CME credit, please follow the steps below: • Sign in to Northwestern University Feinberg School of Medicine’s Office of CME’s website (www.cme.northwestern.edu) using the email and password used to register for this activity. • Click on “My CME” on the top right side of the homepage. • Click on “Evaluation & Certificate.” Choose the activity for which you wish to claim credit and evaluate. You will be asked to enter the number of credits you are claiming. • Once you complete the evaluation form, your certificate will auto-generate. Please print a copy for your records. A copy of your credits will be saved on your transcript that can be found under “My CME” then click “Transcript.” • Please complete the form by Friday, April 2, 2020 in order to receive CME credit. Questions Please contact [email protected] with questions. TARGET AUDIENCE: This activity is intended for healthcare professionals involved in the treatment and care of patients with advanced or refractory cancers for whom precision medicine can help guide treatment choices. This includes medical, surgical, and radiation oncologists, pathologists, radiologists, other translational-oriented laboratory scientists, nurses, pharmacists, and physician assistants. LEARNING OBJECTIVES: (1) Define and discuss the use of clinical genomics and its use in the personalization of treatment for patients with both solid tumors and hematologic malignancies. (2) Identify emerging approaches to acquiring and analyzing genomic information.(3) Describe, discuss, and illustrate the roles of genomic sequencing, molecular analysis with standard pathology, precisely targeted treatments and clinical trials, and the benefits they confer on patients.(4) Define both the challenges and the opportunities faced in the implementation of genomic sequencing in the treatment of cancer patients. ACCREDITATION STATEMENT: The Northwestern University Feinberg School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. CREDIT DESIGNATION STATEMENT: The Northwestern University Feinberg School of Medicine designates this live activity for a maximum of 6.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. OTHER CREDITS: The American Academy of Nurse Practitioners and the American Nurses Credentialing Center accept AMA PRA Category 1 Credits(s)™ from organizations accredited by the ACCME..